WebSep 24, 2024 · Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer cells. Among them, we can find mutations, … WebSep 15, 2024 · Pd(II)-compounds are presently regarded as promising anticancer drugs, as an alternative to Pt(II)-based drugs (e.g., cisplatin), which typically trigger severe side-effects and acquired resistance. Dinuclear Pd(II) complexes with biogenic polyamines such as spermine (Pd 2 Spm) have exhibited particularly beneficial cytotoxic properties, hence ...
Junshi Biosciences Announces Acceptance of the Supplemental …
WebSep 18, 2024 · National Center for Biotechnology Information WebCisplatin and derivatives have been one of the most successful therapies in spite of their side effects and low specificity. Some of the drugs developed after cisplatin discovery, have been targeted the epidermal growth factor receptor, anaplastic lymphoma kinase, programmed cell death 1 ligand and … greater change
Lung Cancer Growth Suppressed by Anticancer and Antifibrotic …
WebCisplatin is a platinum chemotherapeutic used in a variety of malignancies. The antineoplastic activity occurs from DNA cross-links and adducts, in addition to the … WebCisplatin, a class of platinum-containing anticancer drugs for the treatment of solid tumors, is a substrate of OCT2 and MATE1/MATE2-K. OCT2 is expressed in the basolateral membrane of proximal tubules and mediates the transport of cisplatin from the blood to proximal tubule cells. WebCisplatin-based chemotherapy is the standard of care for patients with muscle-invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely understood. greater change crawley